Zobrazeno 1 - 10 of 34 pro vyhledávání: '"Michał Gniot"'
1
Akademický článek
B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib
Autor: Krzysztof Lewandowski, Michał Gniot, Maria Lewandowska, Anna Wache, Błażej Ratajczak, Anna Czyż, Małgorzata Jarmuż-Szymczak, Mieczysław Komarnicki
Publikováno v: Case Reports in Medicine, Vol 2016 (2016)
The coexistence of two diseases chronic myeloid leukemia (CML) and B-cell chronic lymphocytic leukemia (B-CLL) is a rare phenomenon. Both neoplastic disorders have several common epidemiological denominators (they occur more often in men over 50 year
Externí odkaz: https://doaj.org/article/dfa939adc8b34da5b7d2f1f5d49cfe8a
Zobrazit plný text záznamu
2
Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach
Autor: Marzena Wojtaszewska, Rafał Stępień, Alicja Woźna, Maciej Piernik, Pawel Sztromwasser, Maciej Dąbrowski, Michał Gniot, Sławomir Szymański, Maciej Socha, Piotr Kasprzak, Rafał Matkowski, Paweł Zawadzki
Publikováno v: Molecular Diagnosis & Therapy
Background and Objective Human epidermal growth factor receptor 2 (HER2) protein overexpression is one of the most significant biomarkers for breast cancer diagnostics, treatment prediction, and prognostics. The high accessibility of HER2 inhibitors
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c795aa3c103ff9f08e2b6513868be4
http://europepmc.org/articles/PMC8766398
Zobrazit plný text záznamu
3
Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels
Autor: Krzysztof Lewandowski, Zuzanna Kanduła, Michał Gniot, Edyta Paczkowska, Paulina Maria Nawrocka, Marzena Wojtaszewska, Michał Janowski, Magdalena Mariak, Luiza Handschuh, Piotr Kozlowski
Publikováno v: Annals of hematology. 101(12)
It has been postulated that the changes in the molecular characteristics of the malignant clone(s) and the abnormal activation of JAK-STAT signaling are responsible for myeloproliferative neoplasm progression to more advanced disease phases and the i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec1c8b39a3cef44b06882ab2287bead9
https://pubmed.ncbi.nlm.nih.gov/36266510
Zobrazit plný text záznamu
4
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways
Autor: Michał Janowski, Zofia Ulańczyk, Karolina Łuczkowska, Anna Sobuś, Dorota Rogińska, Ewa Pius-Sadowska, Michał Gniot, Krzysztof Kozłowski, Krzysztof Lewandowski, Grzegorz Helbig, Bogusław Machaliński, Edyta Paczkowska
Publikováno v: OncoTargets and therapy. 15
Michał Janowski,1,* Zofia Ulańczyk,2,* Karolina Łuczkowska,2 Anna Sobuś,2 Dorota Rogińska,2 Ewa Pius-Sadowska,2 Michał Gniot,3 Krzysztof Kozłowski,4 Krzysztof Lewandowski,3 Grzegorz Helbig,5 Bogusław Machaliński,2 Edyta Pac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78b38f5cc97cc7b44e9cc51656d9734d
https://pubmed.ncbi.nlm.nih.gov/36238136
Zobrazit plný text záznamu
5
PD-L1 and JAK2 mRNA level in essential thrombocythaemia depends on the driver mutational status and the bone marrow fibrosis grade
Autor: Krzysztof Lewandowski, Zuzanna Kanduła, Michał Gniot, Edyta Paczkowska, Paulina Maria Nawrocka, Marzena Wojtaszewska, Michał Janowski, Magdalena Mariak, Luiza Handschuh, Piotr Kozlowski
Background: JAK-STAT pathway activation leads to an enhanced activity of the promoter of CD274 (PDL1) coding programmed death-1 receptor ligand (PD-L1), increased PD-L1 level and the immune escape of myeloproliferative neoplasms (MPN) cells. It has b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ed003b5d7df8192fd190d1ec23fe2c8
https://doi.org/10.21203/rs.3.rs-1347762/v1
Zobrazit plný text záznamu
7
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry
Autor: Marek Dudziński, Justyna Gil, Iwona Pietkun, Krzysztof Giannopoulos, Joanna Niesiobedzka-Krezel, Joanna Góra-Tybor, Grażyna Bober, Ewa Wasilewska, Ewa Mędraś, Jadwiga Hołojda, Tomasz Sacha, Monika Szarejko, Olga Grzybowska-Izydorczyk, Krzysztof Myśliwiec, Joanna Wącław, Michał Gniot
Publikováno v: American Journal of Hematology. 92:E125-E128
The efficacy and safety of imatinib generics were not studied and reported on larger cohort of patients yet. We report on efficacy and safety of imatinib generics in 726 chronic myeloid leukemia patients in chronic phase who completed one-year observ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99527603be443da2fe4f20dd5d1ff423
https://doi.org/10.1002/ajh.24748
Zobrazit plný text záznamu
8
Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay
Autor: Vibe Skov, Mikkel H Dorff, Michał Gniot, Morten Andersen, Lene Udby, Hans Carl Hasselbalch, Lasse Kjær, Anni Aggerholm, Niels Pallisgaard, Karen Soeby, Philippe Clair
Publikováno v: Kjaer, L, Skov, V, Andersen, M T, Aggerholm, A, Clair, P, Gniot, M, Soeby, K, Udby, L, Dorff, M H, Hasselbalch, H & Pallisgaard, N 2019, ' Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay ', European Journal of Haematology, vol. 103, no. 1, pp. 26-34 . https://doi.org/10.1111/ejh.13238
Objective: Molecular monitoring of treatment response in patients with chronic myelogenous leukemia is performed using the Europe Against Cancer (EAC) qPCR assay using the International Scale (IS). The assay amplifies both e13a2 and e14a2 BCR-ABL1 tr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d892f3d73ab3e87b5c796ebc3c8eb1a1
https://pure.au.dk/portal/da/publications/variantspecific-discrepancy-when-quantitating-bcrabl1-e13a2-and-e14a2-transcripts-using-the-europe-against-cancer-qpcr-assay(ae939960-9361-465c-969e-5ce09fb5087d).html
Zobrazit plný text záznamu
9
Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm
Autor: Monika Pepek, Michał Gniot, Tomasz Stoklosa, Marcin M Machnicki, Andrzej Szczepaniak, Krzysztof Lewandowski, Rafał Płoski, Maciej Kaźmierczak, Małgorzata Rydzanicz
Publikováno v: International journal of hematology. 110(1)
Neurofibromatosis type 1 is an autosomal dominantly inherited tumor predisposition syndrome, in which inactivating mutations in the neurofibromatosis type 1 gene (NF1) lead to a prolonged activation of the signaling via the RAS/RAF/MAPK pathway leadi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9711aa1c37de94d1fbc0227ad6942396
https://pubmed.ncbi.nlm.nih.gov/30977107
Zobrazit plný text záznamu
10
Limfocytoza CD4+CD8+ oraz wysięki osierdziowy i opłucnowy u chorego na przewlekłą białaczkę szpikową w fazie przewlekłej leczonego dazatynibem z powodu niepowodzenia terapii imatynibem
Autor: Błażej Ratajczak, Anna Czyż, Krzysztof Lewandowski, Michał Gniot, Mieczysław Komarnicki, Agata Lehman-Kopydłowska
Publikováno v: Hematologia. 6:301-307
Stosowanie inhibitorow kinaz tyrozynowych u chorych na przewleklą bialaczke szpikową (CML) moze prowadzic do zmian w ukladzie immunologicznym. W pracy przedstawiono przebieg choroby u pacjenta w fazie przewleklej CML leczonego interferonem a, a nas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65b855daa54e3169cb5a461f94c4aac4
https://doi.org/10.5603/hem.2015.0041
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje